Oppenheimer Maintains Outperform on UroGen Pharma, Lowers Price Target to $52

Oppenheimer maintains UroGen Pharma (NASDAQ:URGN) with a Outperform and lowers the price target from $62 to $52.

Benzinga · 01/13/2020 14:11

Oppenheimer maintains UroGen Pharma (NASDAQ:URGN) with a Outperform and lowers the price target from $62 to $52.